Pentixapharm Completes Capital Increase – New Shares Placed in Full

Pentixapharm completes capital increase and raises total gross proceeds of approximately EUR 20.4 Million from full placement of new shares to advance PANDA Phase 3

Proceeds support key Phase 3 activities and U.S. expansion following FDA “Study May Proceed” and Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor

Berlin, July 27, 2026 - Pentixapharm Holding AG, Berlin (ISIN DE000A40AEG0, WKN A40AEG), today announced the completion of the capital increase comprising the rights offering and subsequent private placement launched on July 1, 2026. In total, 11,020,212 new registered no-par value shares were placed at a price of EUR 1.85 per new share. The offering was substantially oversubscribed so that all offered shares could be placed, generating gross issue proceeds of approximately EUR 20.4 million.

The completion of the financing follows two important U.S. regulatory milestones for [⁶⁸Ga]Ga-PentixaFor. In June 2026, the U.S. Food and Drug Administration (FDA) completed its 30-day review of the Investigational New Drug (IND) application for the U.S. Phase 3 PANDA study and allowed the study to proceed (“Study May Proceed”). In July 2026, the FDA granted Fast Track designation to [⁶⁸Ga]Ga-PentixaFor for the diagnostic subtyping of adult patients with confirmed primary aldosteronism.

Dr. Dirk Pleimes, CEO of Pentixapharm, commented: “The completion of this financing provides additional resources to advance key activities in PANDA Phase 3 and our expansion in the United States. It also gives us a stronger starting point as we intensify our evaluation of partnership and out-licensing opportunities, particularly in the U.S. The strong overall interest and high subscription rate demonstrate that, since its spin-off from Eckert & Ziegler SE, Pentixapharm has developed a shareholder structure that fully supports the company’s strategy. We would like to express our sincere thanks to our existing shareholders and new investors for this.”

PANDA is a U.S.-focused, pivotal Phase 3 registrational study designed to evaluate [⁶⁸Ga]Ga-PentixaFor PET/CT as a non-invasive imaging approach for subtyping adult patients with confirmed primary aldosteronism and supporting treatment decisions between surgical and long-term medical management. Pentixapharm is preparing to initiate PANDA in the second half of 2026. Fast Track designation provides for more frequent interaction with the FDA during development and may support a more efficient regulatory review process if the relevant criteria are met.

Pentixapharm intends to use the net issue proceeds primarily to finance key steps of the PANDA Phase 3 study, as well as the Company’s further corporate development and expansion in the U.S. market. A further portion of the net issue proceeds is intended to be used for the continued preparation of clinical development activities and to strengthen the Company’s manufacturing and supply infrastructure. These measures are intended to support the late-stage clinical development of the Company’s programs and further build the foundation for potential future commercialization.

In addition, Pentixapharm intends to use proceeds to further develop its CXCR4-based theranostic platform, including PentixaTher in hematologic oncology indications. Finally, the proceeds are intended to strengthen the Company’s equity base and to fund general corporate purposes and working capital beyond the first quarter of 2027.

During the subscription period from July 7, 2026 to July 21, 2026, subscription rights were exercised for 9,096,771 new shares, including shares acquired through the oversubscription offer. This represented 82.5% of the total planned volume of the capital increase and generated gross issue proceeds of approximately EUR 16.8 million from the rights offering alone. Following the close of the private placement on July 27, 2026, all of the remaining 1,923,441 new shares were placed with selected qualified institutional investors. Pentixapharm’s major shareholder, Eckert Wagniskapital und Frühphasenfinanzierung GmbH, fully exercised its subscription rights as previously announced. The rights offering and private placement were accompanied by BankM AG as lead manager and by NuWays as selling agent.

The Company’s share capital will increase from EUR 24,795,477.00 by EUR 11,020,212 to EUR 35,815,689 following registration of the implementation of the capital increase. The transaction was carried out by making partial use of the Company’s Authorized Capital. After deduction of estimated transaction costs of approximately EUR 0.75 million, Pentixapharm expects net issue proceeds of approximately EUR 19.65 million.

No securities prospectus was published for the public offering of the new shares or for their admission to trading. In accordance with Regulation (EU) 2017/1129, Pentixapharm published a document containing the information required under Annex IX to Regulation (EU) 2017/1129, which has been available on the Company’s website in the Investors section since July 3, 2026.

About Pentixapharm

Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) is a clinical-stage biotechnology company headquartered in Berlin developing innovative nuclear medicine approaches to help physicians detect, characterize, and treat serious diseases with greater precision. The Company’s compounds are designed to deliver medical radioisotopes specifically to defined biological targets - either for high-resolution molecular imaging or for targeted radioligand therapy.

Pentixapharm’s pipeline is built on CXCR4 targeting, a receptor with strong scientific validation across multiple disease areas, and encompasses diagnostic and therapeutic programs in endocrine, cardiovascular, and oncological indications. The lead program, [⁶⁸Ga]Ga-PentixaFor, is being advanced into the registrational Phase 3 PANDA study for non-invasive subtyping of primary aldosteronism. The PENTHERA program advances the CXCR4-directed theranostic platform into Phase I/II in oncology. Complementing the CXCR4 platform, Pentixapharm is also developing a next-generation antibody platform targeting CD24, an emerging immune checkpoint in difficult-to-treat cancers.

Contact

Pentixapharm Holding AG

Investor Relations

Robert-Rössle-Straße 10

13125 Berlin

Deutschland

E-Mail: ir@pentixapharm.com

Website: www.pentixapharm.com

Important Notice

This announcement does not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for any securities. The public offering of the new shares was made solely on the basis of the subscription offer and the Annex IX document published by the Company.

This announcement is not intended for publication, distribution, or release in or into the United States of America, Australia, Canada, Japan, or any other jurisdiction where such publication, distribution or release would be unlawful.

The new shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act"), and may not be offered or sold in the United States of America or to, or for the account or benefit of, U.S. persons absent registration under, or an applicable exemption from the registration requirements of, the Securities Act. There will be no public offering of the shares in the United States of America.